Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: A real-world study using the Myocardial Infarction National Audit Project (MINAP) database

Heart

Volumn 94, Issue 11, 2008, Pages 1407-1412

  Gale, Christopher P ^a   Manda, S O M ^b   Batin, P D ^c   Weston, C F ^d   Birkhead, J S ^e   Hall, A S ^f  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^d SWANSEA UNIVERSITY   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f Yorkshire Heart Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CEREBROVASCULAR DISEASE; FEMALE; FIBRINOLYTIC THERAPY; HEART INDEX; HEART INFARCTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK REDUCTION; ST SEGMENT ELEVATION; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGED; ARRHYTHMIAS, CARDIAC; ASPIRIN; BLOOD PRESSURE; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL MORTALITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 54349086108     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.127068     Document Type: Article

References (33)

1. British Heart Foundation. Coronary heart disease statistics 2004. http://www.heartstats.org/ 2004.
2. Weaver WD, Simes BJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-8.
3. Nunn CM, O'Neill WW, Bothbaum D, et al. Long-tetm outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial. J Am Coll Cardiol 1999;33:640-6.
4. Zijlstra F, Hoorntje JC, de Boet MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413-9.
5. MINAP Steering Group. How the NHS manages heart attacks April 2005-March 2006. Fifth public report. 2006.
6. Horne S, Weston C, Quinn T, et al. The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). Heart 2007 doi:10.1136/hrt.2007.126821.
7. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311- 22.
8. Newby LK, Rutsch WB, Califf BM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 1996;27:1646-55.
9. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
10. EMERAS (Estudio Murticentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993;342:767-72.
11. Dorsch MF, Lawrance RA, Sapsford RJ, et al. A simple benchmark for evaluating quality of care of patients following acute myocardial infarction. Heart 2001;86:150-4.
12. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001;358:1571-5.
13. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
14. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-67.
15. Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000;101:2231-8.
16. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004;291:2727-33.
17. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-53.
18. Jacobs DR Jr, Kroenke C, Crow R, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation 1999;100:599-607.
19. Krumholz HM, Chen J, Chen YT, et al. Predicting one-year mortality among elderly survivors of hospitalization for an acute myocardial infarction: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol 2001;38:453-9.
20. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-7.
21. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-9.
22. Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:783-9.
23. http://www.rcplondon.ac.uk/college/ceeu/ceeu_ami_home.htm. 2006.
24. Birkhead J, Pearson M, Norris RM. The national audit of myocardial infarction: a new development in the audit process. J Clin Excellence 2002;4:379-85.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
26. Pine M, Jordan HS, Elixhauser A, et al. Enhancement of claims data to improve risk adjustment of hospital mortality. JAMA 2007;297:71-6.
27. Gottlieb S, Boyko V, Zahger D, et al. Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). J Am Coll Cardiol 1996;28:1506-13.
28. Gottlieb S, Boyko V, Zahger D, et al. Smoking and prognosis after acute myocardial infarction in the thrombolytic era (Israeli Thrombolytic National Survey). J Am Coll Cardiol 1996;28:1506-13.
29. Ellis SJ, Adams RF. The cult of the double-blind placebo-controlled trial. Br J Clin Pract 1997;51:36-9.
30. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. Appl Stat 1999;48:313-29.
31. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73.
32. Bradshaw PJ, Ko DT, Newman AM, et al. Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients. Can J Cardiol 2007;23:51-6.
33. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.